Cite
HARVARD Citation
Gibbs, J. et al. (2017). Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). Journal of clinical pharmacology. pp. 616-626. [Online].